Screener
Disc Medicine IRON DISC Zero Nine Seven Four — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Disc Medicine in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Disc Medicine’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:33 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205192
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Bitopertin program external expense | $(9,340) | $(8,435) |
| DISC-0974 program external expense | (8,109) | (6,121) |
| DISC-3405 program external expense | (9,187) | (1,668) |
| Other external research and development expense | (2,165) | (1,832) |
| Internal and other research and development expense | (11,312) | (6,748) |
| Commercial expense | $(8,434) | $(1,921) |
| General and administrative expense | $(9,031) | $(6,858) |
| Stock-based compensation expense | $(11,946) | $(6,363) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Disc Medicine's DISC zero nine seven four — research and development expense?
- Disc Medicine (IRON) reported DISC zero nine seven four — research and development expense of $8.11M in Q1 2026.
- How has Disc Medicine's DISC zero nine seven four — research and development expense changed year-over-year?
- Disc Medicine's DISC zero nine seven four — research and development expense increased by 32.5% year-over-year, from $6.12M to $8.11M.
- What is the long-term trend for Disc Medicine's DISC zero nine seven four — research and development expense?
- Over 2 years (2023 to 2025), Disc Medicine's DISC zero nine seven four — research and development expense has grown at a 73.8% compound annual growth rate (CAGR), from $9.14M to $27.59M.
- What does DISC zero nine seven four — research and development expense mean?
- This metric represents the total operating costs directly attributable to the research and development activities for the specific therapeutic candidate or program. It captures the investment in clinical trials, preclinical studies, and regulatory efforts required to advance this specific asset toward commercialization. Monitoring this expense helps investors assess the capital intensity and progress of the company's pipeline development for this particular hematologic treatment.
Ask your AI about Disc Medicine's disc zero nine seven four — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude